On September 14, 2026 Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") reported that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The three presentations address distinct questions about Annamycin: where it concentrates in the body, how it kills cancer cells, and whether it can also enlist the immune system to do so. Together they inform the Company’s development of Annamycin in hard-to-treat cancers.
Title: "Antitumor activity of ANNAMYCIN, a highly effective lipophilic DNA-binding drug: Impact of its organotropism"
Author/Presenter: Waldemar Priebe, PhD, UT MD Anderson Cancer Center
Congress: XIII Congress of the Polish Medical Diaspora
Dates: September 9-12, 2026
Location: Wroclaw, Poland
Annamycin’s lipophilic structure drives it to concentrate in specific tissues rather than distribute uniformly. Dr. Priebe’s presentation examines how that distribution relates to the antitumor activity observed across preclinical models, and what it may mean for treating tumors in those tissues.
Title: "Organotropism-guided exploration of anticancer properties of Annamycin (naxtarubicin), a potent topoisomerase II targeting agent"
Author/Presenter: Waldemar Priebe, PhD, UT MD Anderson Cancer Center
Event: Invited Lecture at the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
Date: September 14, 2026
Location: Wroclaw, Poland
This invited lecture extends the same line of inquiry to mechanism, examining how Annamycin’s tissue distribution interacts with its inhibition of topoisomerase II, the enzyme target through which anthracyclines produce DNA damage in dividing cells.
Title: "Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by CD8+ T cell cytotoxicity"
Author/Presenter: Angela T. Alistar, MD, Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center
Congress: AACR (Free AACR Whitepaper) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development
Dates: September 25-28, 2026
Location: Hilton San Diego Bayfront, San Diego, California
The abstract for this presentation remains under embargo until publication. Moleculin expects to report on the findings when the abstract is published, as described below.
Abstracts selected for presentation at the AACR (Free AACR Whitepaper) Conference on Pancreatic Cancer will be published as a supplement to the September 15, 2026 issue of Cancer Research on September 25, 2026, at 1:00 p.m. ET.
"Annamycin’s ability to concentrate in specific tissues is one of the properties that most distinguishes it from currently prescribed anthracyclines, and it is the through-line across these presentations," said Walter Klemp, Chairman, President and Chief Executive Officer of Moleculin. "Having this work presented by leading investigators, and accepted at an AACR (Free AACR Whitepaper) conference, reflects the breadth of scientific interest in Annamycin beyond our lead indication in AML."
These presentations run alongside Moleculin’s lead clinical program, the ongoing MIRACLE trial evaluating AnnAraC in patients with relapsed or refractory acute myeloid leukemia (AML). MIRACLE remains the Company’s primary development focus and the basis of its near-term milestones.
(Press release, Moleculin, SEP 14, 2026, View Source [SID1234670820])